Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2020 Nov 1;75(11):3373-3378.
doi: 10.1093/jac/dkaa332.

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Hamideh Abbaspour Kasgari  1 , Siavash Moradi  2 , Amir Mohammad Shabani  1 , Farhang Babamahmoodi  3 , Ali Reza Davoudi Badabi  3 , Lotfollah Davoudi  3 , Ahmad Alikhani  3 , Akbar Hedayatizadeh Omran  4 , Majid Saeedi  5 , Shahin Merat  6 , Hannah Wentzel  7 , Anna Garratt  8 , Jacob Levi  9 , Bryony Simmons  10 , Andrew Hill  11 , Hafez Tirgar Fakheri  12
Affiliations
Randomized Controlled Trial

Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial

Hamideh Abbaspour Kasgari et al. J Antimicrob Chemother. .

Abstract

Background: New therapeutic options are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19). Repurposing existing pharmaceuticals provides an immediate treatment opportunity. We assessed the efficacy of sofosbuvir and daclatasvir with ribavirin for treating patients with COVID-19.

Methods: This was a single-centre, randomized controlled trial in adults with moderate COVID-19 admitted to the Ghaem Shahr Razi Hospital in Mazandaran Province, Iran. Patients were randomly assigned to 400 mg sofosbuvir, 60 mg daclatasvir and 1200 mg ribavirin (intervention group) or to standard care (control group). The primary endpoint of this study was length of hospital stay. This study is registered by IRCT.ir under the ID: IRCT20200328046886N1.

Results: Between 20 March 2020 and 8 April 2020, 48 patients were recruited; 24 patients were randomly assigned to the intervention group and 24 to the control group. The median duration of hospital stay was 6 days in both groups (P = 0.398). The number of ICU admissions in the sofosbuvir/daclatasvir/ribavirin group was not significantly lower than the control group (0 versus 4, P = 0.109). There was no difference in the number of deaths between the groups (0 versus 3, P = 0.234). The cumulative incidence of recovery was higher in the sofosbuvir/daclatasvir/ribavirin arm (Gray's P = 0.033).

Conclusions: This randomized trial was too small to make definitive conclusions. There were trends in favour of the sofosbuvir/daclatasvir/ribavirin arm for recovery and lower death rates. However, there was an imbalance in the baseline characteristics between the arms. Larger randomized trials should be conducted to investigate this treatment further.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Trial profile.
Figure 2.
Figure 2.
Cumulative incidence of recovery by treatment arm. SOF/DCV/RBV, sofosbuvir/daclatasvir/ribavirin.
See this image and copyright information in PMC

References

    1. Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. - PMC - PubMed
    1. Park M, Cook AR, Lim JT. et al. A systematic review of COVID-19 epidemiology based on current evidence. J Clin Med 2020; 9: 967. - PMC - PubMed
    1. Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems. Infect Control Hosp Epidemiol 2020; 41: 754–5. - PMC - PubMed
    1. WHO. WHO COVID-19 Data Explorer. https://covid19.who.int/explorer.
    1. Geleris J, Sun Y, Platt J. et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med 2020; 382: 2411–8. - PMC - PubMed

Publication types

MeSH terms